Medication therapy management of a diabetic patient complicated with cardiovascular disease

SI Jigang; SUN Xue; ZHANG Jianqiao; WEI Yedong; WANG Yuexuan

doi:10.6039/j.issn.1001-0408.2024.19.16

您当前的位置：

首页 >

文章列表页 >

Medication therapy management of a diabetic patient complicated with cardiovascular disease

更新时间：2024-10-11

- Medication therapy management of a diabetic patient complicated with cardiovascular disease
- ZHONGGUO YAOFANG Vol. 35, Issue 19, Pages: 2416-2421(2024)
- 作者机构：
  
  淄博市中心医院药学部，山东淄博　255036
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.19.16
  CLC： R969.3;R977;R972
- Published：15 October 2024，
  
  Received：26 March 2024，
  
  Revised：18 August 2024，
- 稿件说明：
移动端阅览
司继刚,孙雪,张剑桥等.1例糖尿病合并心血管疾病患者的药物治疗管理 ^Δ[J].中国药房,2024,35(19):2416-2421.

SI Jigang,SUN Xue,ZHANG Jianqiao,et al.Medication therapy management of a diabetic patient complicated with cardiovascular disease[J].ZHONGGUO YAOFANG,2024,35(19):2416-2421.
司继刚,孙雪,张剑桥等.1例糖尿病合并心血管疾病患者的药物治疗管理 ^Δ[J].中国药房,2024,35(19):2416-2421. DOI： 10.6039/j.issn.1001-0408.2024.19.16.

SI Jigang,SUN Xue,ZHANG Jianqiao,et al.Medication therapy management of a diabetic patient complicated with cardiovascular disease[J].ZHONGGUO YAOFANG,2024,35(19):2416-2421. DOI： 10.6039/j.issn.1001-0408.2024.19.16.

摘要

目的

为糖尿病合并心血管疾病患者的药物治疗管理（MTM）提供参考。

方法

1例63岁男性糖尿病患者行冠状动脉介入术后因每日上午出现一过性头痛到我院神经内科就诊，并被推荐到药学门诊。药学门诊药师分析后认为，患者出现的头痛症状、严重便秘和高尿酸血症很可能与其所用药物有关；进一步发现患者血压、心率、血糖和血脂等动脉粥样硬化性心血管疾病影响因素均未达标。药师通过药学问诊与药品不良反应的判断、用药评估、药物重整、用药宣教和药学随访等为患者提供MTM服务。

结果

药师经过13周15次的MTM服务，重整优化了药物治疗方案，停用了引起药品不良反应的药物单硝酸异山梨酯缓释片、硝苯地平控释片和吲达帕胺片，使患者用药品种数由15种调减至7种。患者头痛症状消失，严重便秘症状明显改善，血尿酸降至正常范围；血压、心率、空腹血糖、糖化血红蛋白、低密度脂蛋白胆固醇和尿酸等动脉粥样硬化性心血管疾病影响因素分别由MTM服务前的＞140/90 mmHg（1 mmHg＝0.133 kPa）、70～80次/min、7.71 mmol/L、7.2%、2.13 mmol/L和494 μmol/L降至MTM服务后的＜130/80 mmHg、55～60次/min、6.22 mmol/L、6.3%、1.55 mmol/L和348 μmol/L。

结论

药师为患者提供MTM服务，可提高患者生活质量和治疗效果，降低用药风险，提升医院药物合理应用水平和临床药学服务能力。

Abstract

OBJECTIVE

To provide reference for medication therapy management （MTM） of diabetic patients complicated with cardiovascular disease.

METHODS

A 63-year-old male diabetic patient who suffered from temporary headache every morning after percutaneous coronary intervention （PCI） visited the neurology department of our hospital， and then was recommended to the pharmaceutical outpatient department. The pharmacists thought that the patient’s symptoms of headache， severe constipation and hyperuricemia were more likely induced by the medication used. The pharmacists further found that his atherosclerotic cardiovascular disease （ASCVD） influencing factors such as blood pressure， heart rate， blood glucose and blood lipids did not reach standard. The pharmacists provided MTM services for the patient through pharmacy inquiry and adverse drug reactions judgement， medication evaluation， medication reconciliation， medication education and pharmacy follow-up.

RESULTS

Through fifteen MTM services for thirteen weeks， the pharmacists reconciliated and optimized the medication therapy plan， discontinued the use of Isosorbide mononitrate sustained-release tablets， Nifedipine controlled-release tablets， and Indapamide tablets， which caused adverse drug reactions； the number of drugs was adjusted from fifteen to seven， and the symptom of headache disappeared； severe constipation had also been significantly improved， and hyperuricemia dropped to normal range. The ASCVD influencing factors of blood pressure， heart rate， fasting plasma glucose， glycosylated hemoglobin， low-density lipoprotein cholesterol and uric acid were reduced from ＞140/90 mmHg（1 mmHg＝0.133 kPa）， 70-80 beats per minute， 7.71 mmol/L， 7.2%， 2.13 mmol/L and 494 μmol/L before MTM services to ＜130/80 mmHg， 55-60 beats per minute， 6.22 mmol/L， 6.3%， 1.55 mmol/L and 348 μmol/L after MTM services.

CONCLUSIONS

The pharmacists providing MTM services to the patients can improve their quality of life and therapeutic efficacy， reduce medication risks， and enhance the level of rational drug use in hospitals and pharmaceutical service capabilities.

关键词

药物治疗管理药学门诊糖尿病心血管疾病药物重整

Keywords

pharmaceutical outpatient departmentdiabetescardiovascular diseasedrug reconciliation

references

WIJEYSUNDERA H C，MACHADO M，FARAHATI F，et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality，1994-2005[J]. JAMA，2010，303（18）：1841-1847.

PU L J，LU L，ZHANG R Y，et al. Glycation of apoprotein A-I is associated with coronary artery plaque progression in type 2 diabetic patients[J]. Diabetes Care，2013，36（5）：1312-1320.

ASSOCIATION A P，National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice：core elements of an MTM service model：version 2.0[J]. J Am Pharm Assoc，2008，48（3）：341-353.

OLOFSSON I A，FALKENBERG K，OLESEN J，et al. Headache provocation by nitric oxide in men who have never experienced a headache[J]. Cephalalgia，2022，42（7）：598-607.

AL NOU’MANI J，AL ALAWI A M，AL-MAQBALI J S，et al. Prevalence，recognition，and risk factors of constipation among medically hospitalized patients：a cohort prospective study[J]. Medicine （Kaunas），2023，59（7）：1347.

OHTA Y，KAMIDE K，HANADA H，et al. Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension[J]. Hypertens Res，2020，43：220-226.

中国高血压防治指南修订委员会，王继光. 中国高血压防治指南：2024年修订版[J]. 中华高血压杂志，2024，32（7）：603-700.

Chinese Hypertension Prevention and Treatment Guidelines Revision Committee，WANG J G. Guidelines for prevention and treatment of hypertension in China：revised in 2024[J]. Chin J Hypertens，2024，32（7）：603-700.

中华医学会糖尿病学分会，朱大龙. 中国2型糖尿病防治指南：2020年版[J]. 中华糖尿病杂志，2021，13（4）：315-409.

Chinese Diabetes Society，ZHU D L. Guideline for the prevention and treatment of type 2 diabetes mellitus in China：2020 edition[J]. Chin J Diabetes Mellit，2021，13（4）：315-409.

潘锋. 中国高血压患者心率管理多学科专家共识：2021版[J]. 中国当代医药，2021，28（13）：1-3.

PAN F. Expert consensus of multidisciplinary experts on heart rate management of hypertension patients in China：2021 edition [J]. China Mod Med，2021，28（13）：1-3.

TOMLINSON B，LI Y H，CHAN P. Evaluating gliclazide for the treatment of type 2 diabetes mellitus[J]. Expert Opin Pharmacother，2022，23（17）：1869-1877.

WIVIOTT S D，RAZ I，BONACA M P，et al. Dapag-liflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med，2019，380（4）：347-357.

国家卫生健康委员会能力建设和继续教育中心，孙艺红，陈康，等. 糖尿病患者合并心血管疾病诊治专家共识[J]. 中华内科杂志，2021，60（5）：421-437.

National Health Commission Capacity Building and Continuing Education Center，SUN Y H，CHEN K，et al. Expert consensus on the management of diabetic patients with cardiovascular diseases[J]. Chin J Intern Med，2021，60（5）：421-437.

ONTARGET INVESTIGATORS，YUSUF S，TEO K K，et al. Telmisartan，ramipril，or both in patients at high risk for vascular events[J]. N Engl J Med，2008，358（15）：1547-1559.

孙宁玲，施仲伟，霍勇，等. 高血压合并左心室肥厚诊治专家共识[J]. 中华心血管病杂志，2019，2（1）：15-19.

SUN N L，SHI Z W，HUO Y，et al. Expert consensus on diagnosis and treatment of hypertension complicated with left ventricular hypertrophy[J]. Chin Video J Cardiol，2019，2（1）：15-19.

FOX K，FORD I，STEG P G，et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction （BEAUTIFUL）：a subgroup analysis of a randomised controlled trial[J]. Lancet，2008，372（9641）：817-821.

ZHANG Y J，LI M P，TANG J，et al. Pharmacokinetic and pharmacodynamic responses to clopidogrel：evidences and perspectives[J]. Int J Environ Res Public Health，2017，14（3）：301.

3rdFRELINGER A L，LEE R D，MULFORD D J，et al. A randomized，2-period，crossover design study to assess the effects of dexlansoprazole，lansoprazole，esomeprazole，and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers[J]. J Am Coll Cardiol，2012，59（14）：1304-1311.

杨丽娟，甄健存，黄品芳，等. 药学门诊标准制订与解析[J]. 医药导报，2022，41（10）：1435-1438.

YANG L J，ZHEN J C，HUANG P F，et al. Formulation and analysis on the standard of pharmaceutical clinic[J]. Her Med，2022，41（10）：1435-1438.

杨丽娟，万明媛，张威，等. 我国医疗机构药学门诊开展现状调查[J]. 中国药房，2024，35（2）：134-139.

YANG L J，WAN M Y，ZHANG W，et al. Investigation of the current situation of pharmaceutical clinics in medical institutions in China[J]. China Pharm，2024，35（2）：134-139.

杨烁，邵晓楠，吴岢非，等. 国内外药物重整服务现状及补偿机制探讨[J]. 中国医院，2020，24（5）：60-62.

YANG S，SHAO X N，WU K F，et al. Exploration of the status of domestic and foreign drug reconciliation services and compensation mechanisms[J]. Chin Hosp，2020，24（5）：60-62.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

药物差异的临床研究进展

Current situation of remote pharmaceutical care at home and abroad

Practice of Clinical Pharmacist Participating in Medication Reconciliation for Patients with Chronic Kidney Disease

Related Author

李英华陆悦李利李湘萍

NIU Ziran

HU Yang

YAN Xuelian

QU Jinghan

LIU Rongji

DU Liping

BAI Ziyu

Related Institution

No data

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰